Actavis antibiotic combo Avycaz OK'd for 2 infections
This article was originally published in Scrip
Executive Summary
Actavis won the FDA's approval on 25 February to market Avycaz, an antibiotic combination containing ceftazidime and avibactam, to treat complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).
You may also be interested in...
Merck Looks To Add Pneumonia To Zerbaxa Label; Market Value Not Clear
Merck unveiled Phase III data showing efficacy in hospital-acquired bacterial pneumonia, but branded drugs with this indication currently have not scored significant sales.
Phase III Data Give Medicines Company's Carbavance A Chance To Best Antibiotic Competitors
The Medicines Co. is a few years behind its most recent beta-lactamase inhibitor competitors, but its antibiotic Carbavance is the only one with pivotal data that show superiority to a well-known drug in the same class for the treatment of hospital-based urinary tract infections.
AZ's Zavicefta Gains EU Positive Opinion For “Superbug” Infections
The CHMP followed recent EMA guidance to take a flexible approach to drugs against multi-resistant pathogens when recommending approval for AstraZeneca’s latest antibacterial Zavicefta.